Skip to main content

Mar Tintore Subirana

Institutions of which they are part

Predoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Assistencial
Multiple Sclerosis Centre of Catalonia
Education

PHD, UAB (Autonomous University of Barcelona) (Cum Laude) 20/06/1993
MD, UAB (Autonomous University of Barcelona) 18/06/1987

1991 - 1993 PhD, Doctoral thesis: Antiendothelial cell antibodies in patients with Multiple Sclerosis Autonomous University of Barcelona, Dir. Xavier Montalban Gairín
1981 - 1987 MD Medicine and Surgery, Autonomous University of Barcelona, Barcelona, Spain
1992 - 1995 Associate neurologist and clinical fellow, Department of Neurology, Vall d’Hebron University Hospital, Barcelona, Spain
1992 - 1995 Emergency Deputy, Vall d’Hebron University Hospital, Barcelona, Spain 1988 –
1992 Neurology Resident, MIR Program, Vall d’Hebron University Hospital, Barcelona, Spain

Employment

2012 - Senior Consultant, Clinical Coordinator CEMCAT, Multiple Sclerosis Center of Catalonia, Vall d’Hebron University Hospital, Barcelona, Spain
2012 - Clinical Chief Neurology / Neuroimmunology Department, Vall d’Hebron University Hospital, Barcelona, Spain
2001 - 2012 Neurologist, Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Neurology/Neuroimmunology Department.
1995 - 2001 Neurologist; Neurology Department, Vall d'Hebron University Hospital
1992 - 1995 Emergency Deputy; Vall d'Hebron University Hospital

Professional Experience: 32 years

2021 – Associate Professor of Neurology, UVic - UCC (Vic University - Central University of Catalonia)
2014 - Teacher of the official online Master in Neuroimmunology
2014 - Teacher of the official Master in Immunology
2013 - Teacher of the official Master’s degree in Advanced Immunology

LANGUAGES
Native level: Spanish, Catalan
Proficiency: French, English



Accreditations
Research Certification in Medical and Health Sciences, Neurology, (AQU)

Research Supervision
PhD: 3

Accredited teaching
2009 – present Lecturer, Master Online in Neuroimmunology, UAB
2008 – present Lecturer, Official master’s degree in Advanced Immunology, UB-UAB
2008 - present Lecturer, Official master’s degree in Neuroinmunology – Doctoral program and training activities
2014-2016 Lecturer, Official master’s degree in Translational Biomedical Research, VHIR
2015-2019 Collaborator lecturer, Chair of Neurology / Neuroimmunology, HUVH,
2001-2022 Lecture programmes and tutorship to junior doctors undertaking medical internships and residencies; Vall d'Hebron University Hospital.

Research lines

Susceptibility, diagnostic and prognostic markers in multiple sclerosis

2.1. Search for casual variants of genes associated with MS Lead scientist: Manuel Comabella This line of research seeks to identify causal variants responsible for the MS risk of genes found to be associated with the disease in GWAS by means if deep sequencing. 2.2. To develop dynamic risk scores according to dynamic prognostic models for MS based on clinical, biological and radiological variables Lead scientist: Mar Tintoré In particular: 1. Develop a dynamic risk score based on the evaluation of demographical, clinical, radiological, and biological factors that entail a higher risk of developing a second relapse after a clinically isolated syndrome (CIS), i.e. risk of CDMS, through building models of a dynamic nature. 2. Develop a dynamic risk score based on the evaluation of demographical, clinical, radiological, and biological factors entail a higher risk of progression of disability, as measured by the Expanded Disability Status Scale (EDSS) (Kurtzke Neurology 1983), in people who have suffered a CIS, also through building models of a dynamic nature. Since 1995, patients presenting with a CIS or first attack suggestive of MS are included in a prospective cohort study. One thousand and one hundred CIS patients with a median follow-up of almost 10 years, have been included up to now. Clinical variables (age, gender, topography of the syndrome), radiological variables (number of lesions, number of Barkhof criteria, topography of the lesions, atrophy measures), as well as biological markers (IgG and IgM oligoclonal bands). In a subgroup of patients additional biomarkers (neurofilaments light and heavy chains, fetuin A, GFAP, anti-neurofascin antibodies, anti-glycan panel, chitinase, S1P, etc.) are studied as predictors of conversion to MS and as predictors of disability progression. Mathematical and marginal structural models with different combinations of the variables listed above are investigated. 2.3. Neuropsychological assessment of neurocognitive deficits in patients with multiple sclerosis Lead scientist: Mª Jesús Arévalo Unified neuropsychological assessment is considered necessary to make comparisons between different groups of patients and to draw general conclusions as well as to evolve in the knowledge of cognitive impairment of patients. There is no consensus on protocols for neuropsychological assessment of people with MS in Catalonia and patient evaluations are performed disparately among different hospitals. Neurologists and neuropsychologists from 13 hospitals and patient foundations from Catalonia have held work meetings every two months since July 2012 to seek common work ground. Consensus has been reached as to a common neuropsychological protocol for the assessment of cognitive impairment in MS. We have set up a common database including clinical and neuropsychological variables recorded from interviews with patients introduced into one application. Our work group has been incorporated into the Neuropsychology Section of the Official College of Psychology of Catalonia. 2.4. Upper limbs function and psychometric properties of outcome measures Lead scientist: Núria Filló / Ingrid Galán Upper limbs impairment impacts on daily activities and social participation of persons with MS. Under-recognition of upper limb dysfunction may result in part from limited availability of performance-based and patient self-report measures that are validated for use in MS and that can be readily incorporated into clinical practice for screening and regularly scheduled assessments This line of research seeks to study the psychometric properties of outcome measures for upper limb function in MS. 2.5 EpidEMcat Lead scientist: Susana Otero The Multiple Sclerosis Centre of Catalonia (Cemcat) coordinates a project that aims to characterize the epidemiology of MS in Catalonia. For this purpose, a prospective registry of new cases of MS in Catalonia was set up in 2009 with the participation of 21 hospitals throughout Catalonia. Prevalence and incidence studies based on this population-based registry are being performed. A new research line on co-morbidity and healthcare resource utilization in MS patients is now starting. 2.6 Search of genetic modifiers associated with aggressive and benign disease courses Lead scientist: Manuel Comabella We aim to identify genetic variants that influence the course of the disease by means of exome sequencing of MS patients with divergent clinical courses, i.e. aggressive and benign disease courses. 2.7 Search of biomarkers for multiple sclerosis by RNA, microRNA and exome sequencing approaches Lead scientist: Manuel Comabella Biomarkers are needed in MS to understand the complex and multifactorial heterogeneity of the disease, particularly disease activity biomarkers that may help to distinguish between different MS clinical courses or activity phases of the disease. Here, we aimed to identify disease activity biomarkers in MS by applying RNA, microRNA, and DNA sequencing approaches.

IP: Manuel Comabella Lopez, Mar Tintore Subirana, Jaume Sastre Garriga, M Jesus Arevalo Navines, Susana Otero Romero

Projects

Estudio de comorbilidad y de inmunogenicidad vacunal en una cohorte prospectiva de pacientes con primeros brotes sugestivos de Esclerosis Múltiple

IP: Susana Otero Romero
Collaborators: Juliana Esperalba Esquerra, Mar Tintore Subirana, Laia Pinos Tella, Marta Rodríguez Barranco, Luciana Midaglia Fernandez, Sonia Maria Uriona Tuma, Anna Laura Salerno
Funding agency: Instituto de Salud Carlos III
Funding: 105270
Reference: PI19/01606
Duration: 01/01/2020 - 31/12/2022

Rol of optical coherence tomography in predicting treatment response

IP: Mar Tintore Subirana
Collaborators: Miriam Izquierdo Sans
Funding agency: ECTRIMS
Funding: 55000
Reference: ECTRIMS/HHRR/2019/CARDENAS
Duration: 14/09/2019 - 14/11/2020

"Papel de los factores hormonales relacionados con la mujer en el riesgo y pronóstico de la Esclerosis Múltiple"

IP: Mar Tintore Subirana
Collaborators: -
Funding agency: Fundación Genzyme
Funding: 10000
Reference: GENZYME - 2015-01
Duration: 12/11/2015 - 11/11/2017

Papel de los factores hormonales relacionados con la mujer en el riesgo y pronóstico de la E.M.

IP: Mar Tintore Subirana
Collaborators: Susana Otero Romero, Sunny Malhotra Sareen, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Cristina Auger Acosta, Alex Rovira Cañellas, Joaquin Castillo Justribo, Milagros Fraga Pereira, Georgina Arrambide García
Funding agency: Instituto de Salud Carlos III
Funding: 98615
Reference: PI15/00170
Duration: 01/01/2016 - 31/12/2019

Related news

The research led by Vall d'Hebron is a breakthrough in the search for specific and effective treatments for the disease.

The study conducted at Vall d'Hebron shows that having a high level of neurofilament light chains translates, over the years, to a higher level of disability.

The research aims to identify which patients with isolated radiological syndrome are more likely to develop the disease.

Related professionals

Andrea Serrano Mascarós

Andrea Serrano Mascarós

Research technician
Clinical Neuroimmunology
Read more
Cristina Vetoret Vázquez

Cristina Vetoret Vázquez

Research technician
Clinical Neuroimmunology
Read more
Montserrat Janer Cabo

Montserrat Janer Cabo

Predoctoral researcher
Clinical Neuroimmunology
Read more
José Ant. Graells Salvador

José Ant. Graells Salvador

Administration and Management
Clinical Neuroimmunology
Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.